

Article

Inter-Alpha-Trypsin Inhibitor Heavy Chain 4 Plays an Important Role in the Development and Reproduction of *Nilaparvata lugens*

Jin-Liang Ji [†], Shan-Jie Han [†], Rui-Juan Zhang, Jian-Bin Yu, Ya-Bin Li, Xiao-Ping Yu, Guang-Fu Liu ^{*} and Yi-Peng Xu ^{*}

Zhejiang Provincial Key Laboratory of Biometrology and Inspection & Quarantine, China Jiliang University, Hangzhou 310018, China; j1793505637@163.com (J.-L.J.); hanshanjie@126.com (S.-J.H.); 18893781226@163.com (R.-J.Z.); y17857687285@163.com (J.-B.Y.); lyb13372418590tt@163.com (Y.-B.L.); yxp@cjlu.edu.cn (X.-P.Y.)

^{*} Correspondence: lgf@cjlu.edu.cn (G.-F.L.); yxp@cjlu.edu.cn (Y.-P.X.); Tel.: +86-0571-8683-5700 (G.-F.L. & Y.-P.X.)

[†] These authors contributed equally to this work and should be considered co-first authors.

Simple Summary: The brown planthopper, *Nilaparvata lugens* (Hemiptera: Delphacidae), is a destructive insect pest of rice. It causes reductions in rice yield and great economic losses. In this study, we used RNAi to explore the function of the inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) gene in the development and reproduction of the brown planthopper. Our results revealed that *ITIH4* influences the survival, ovarian development, egg production, and egg hatching of this insect, indicating that *ITIH4* plays important roles in development and reproduction. Considering the importance of *ITIH4* in the brown planthopper, it may be a potential target for pest management.

Abstract: The brown planthopper, *Nilaparvata lugens*, is a difficult-to-control insect pest affecting rice yields in Asia. As a structural component of the inter-alpha-trypsin inhibitor (ITI), the inter-alpha-trypsin inhibitor heavy chain (ITIH) has been reported to be involved in various inflammatory or malignant disorders, ovarian development, and ovulation. To reveal the function of ITIH4 in *N. lugens*, the gene encoding *N. lugens* ITIH4 (*NIITIH4*) was cloned and characterized. *NIITIH4* contains a signal peptide, a vault protein inter-alpha-trypsin domain, and a von Willebrand factor type A domain. qPCR analysis showed that *NIITIH4* was expressed at all developmental stages and in all tissues (fat body, ovary, and gut), with the highest expression in the fat body. Double stranded *NIITIH4* (ds*NIITIH4*) injection clearly led to an RNAi-mediated inhibition of the expression of *NIITIH4* and resulted in reduced survival, delayed ovarian development, and reduced egg production and egg hatching. These results indicate that *NIITIH4* plays an important role in the development and reproduction of *N. lugens*.

Keywords: *Nilaparvata lugens*; inter-alpha-trypsin inhibitor heavy chain 4; RNAi; development; reproduction



Citation: Ji, J.-L.; Han, S.-J.; Zhang, R.-J.; Yu, J.-B.; Li, Y.-B.; Yu, X.-P.; Liu, G.-F.; Xu, Y.-P. Inter-Alpha-Trypsin Inhibitor Heavy Chain 4 Plays an Important Role in the Development and Reproduction of *Nilaparvata lugens*. *Insects* **2022**, *13*, 303. <https://doi.org/10.3390/insects13030303>

Academic Editor: Geoffrey M. Attardo

Received: 31 January 2022

Accepted: 15 March 2022

Published: 18 March 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The brown planthopper (BPH), *Nilaparvata lugens*, is one of the most destructive insect pests affecting rice yields in Asia. It feeds exclusively on rice sap and causes serious losses of rice yields via its spawning activities and by transmitting rice viruses. The application of chemical pesticides and the cultivation of resistant rice varieties are typical measures enacted to control *N. lugens*. However, as a migratory insect, *N. lugens* is an *r*-strategic species with high fecundity, and it also develops strong resistance to pesticides and resistant rice varieties, making effective control of *N. lugens* a difficult endeavor [1,2].

Inter-alpha-trypsin inhibitor family proteins (ITI) have inhibitory activity against trypsin and were initially discovered in serum and urine. They are composed of a common light chain called bikunin and multiple closely related heavy chains (ITIHs) [3–6].

Bikunin is generally linked to one or two ITIHs, and these complexes form the typical protein-glycosaminoglycan-protein (PGP) structure of ITI [6–8]. Bikunin inhibits a wide range of proteases, such as trypsin, granulocyte elastase, plasmin, and cathepsin, and it plays a role in inhibiting urolithiasis, suppressing tumorigenesis and metastasis, and preventing postoperative stress and shock [6,9]. Bikunin has been widely studied, but there is not much research on ITIH. Studies have shown that ITIH is associated with various diseases, including the inflammatory response in local tissues, acute inflammation, and the development of tumors [6]. As the main part of ITI, ITIH was also found to play a significant role alone or in combination with bikunin in subsequent studies [6].

An important function of ITIH involves its ability to esterify with hyaluronic acid (HA) [10–13]. HA interacts with other extracellular matrix molecules to form a network structure to maintain the stability of the extracellular matrix, and it has an important impact on cell properties, migration, and tumor metastasis [13–15]. The ITIH-HA complex is believed to protect joints from inflammatory damage possibly caused by free oxygen radicals in arthritis [16]. In ovarian development and ovum maturation, the construction of the cumulus cell matrix also requires the formation of the ITIH-HA complex in some mammals, including humans, mice, and pigs [17–19]. In fact, a study that involved a mouse knockout of the *bikunin* gene showed that ITIH-HA is crucial for ovulation and fertilization [18]. ITIH4 from human and pig plasma has also been confirmed as a substrate for the plasma serine protease kallikrein [17,20]. ITIH4 has been established as an atypical acute phase protein (APP) that can inhibit actin polymerization and phagocytosis of polymorphonuclear cells [21], and it is also associated with various malignant diseases and inflammatory conditions [6,21–23]. ITIH4 may function as an APP for the protection of the uterus from the inflammatory response in pig endometrium [17]. Furthermore, ITIH4 has also been extensively studied as a biomarker in cancers and other disorders and in other biological contexts [24–28]. Despite the significance of ITIH4 in mammals, research regarding the function of this protein in insects has not been reported.

In a previous experiment, we found that *N. lugens* ITIH4 (*NIITIH4*) was highly expressed in the ovary and that *NIITIH4* was most highly expressed during vitellogenesis, implying that *NIITIH4* may be related to the reproduction of *N. lugens*. Understanding the reproduction of *N. lugens* is essential for its management. Therefore, in the present study, we cloned the *NIITIH4* and analyzed its protein sequence, and then investigated the function of *NIITIH4* in female *N. lugens*.

2. Materials and Methods

2.1. Experimental Insects

The *N. lugens* population used in this study was originally collected from a rice field in Yuyao (Zhejiang province, China), and the insects were maintained in a climatron at China Jiliang University for 10 years. The insects were reared on rice seedlings (Taichung Native 1, TN1) at 27 ± 1 °C with $75 \pm 5\%$ humidity under a 14 h light, 10 h dark photoperiod.

2.2. Cloning the cDNA of *NIITIH4*

Total RNA was extracted from five adult females with a TaKaRa MiniBEST Universal RNA Extraction Kit (Takara, Dalian, China). RNA quality was verified by electrophoresis on a 1% agarose gel and the RNA was quantified with a NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA, USA). A sample (1 µg) of total RNA was used to synthesize cDNA by removing genomic DNA and then performing reverse transcription with a TaKaRa PrimeScriptTM RT reagent Kit with gDNA Eraser (Takara, Dalian, China). The cDNA synthesis reaction consisted of a 10 µL reaction volume (1 µL gDNA Eraser, 2 µL 5× gDNA Eraser Buffer, 1 µg sample RNA and RNase Free dH₂O) that was incubated at 42 °C for 2 min. Another 10 µL reaction volume, which included 1 µL PrimeScript RT Enzyme Mix I, 2 µL RT Primer Mix, 2 µL Oligo dT Primer, and 1 µL RNase Free dH₂O, was added, and the mixture was incubated at 37 °C for 15 min and 85 °C for 5 s and cooled to 4 °C.

The synthesized cDNA solution was diluted 10-fold and used as a template for PCR. Based on the *NIITIH4* sequence from our transcriptome database, a specific primer pair was designed by using Primer Premier 5.0 (Table 1), and PCR was performed with TaKaRa Ex Taq (Takara, Dalian, China). The PCR reaction was conducted in a 50 μ L reaction volume, which included 0.25 μ L TaKaRa Ex Taq, 1 μ L forward and reverse primers, 5 μ L 10 \times Ex Taq Buffer, 4 μ L dNTP mixture, 1 μ L cDNA template, and 39.75 μ L sterilized ddH₂O. The PCR program was: 94 $^{\circ}$ C for 3 min; followed by 35 cycles of 94 $^{\circ}$ C for 30 s, 56 $^{\circ}$ C for 30 s and 72 $^{\circ}$ C for 3 min; and 72 $^{\circ}$ C for 10 min. The PCR product was recovered with a TaKaRa MiniBEST Agarose Gel DNA Extraction Kit (Takara, Dalian, China) and cloned into a pMD19-T vector (Takara, Dalian, China). The construct was sequenced by Shanghai Sangon Biological Engineering Technology (Sangon, Shanghai, China).

Table 1. The primers used in this study.

Primers	Primer Sequence (5'–3')	Product Length
For cDNA cloning: <i>NIITIH4</i> -F	TTTTGCTAACATTTTCCTCCTTG	2798 bp
<i>NIITIH4</i> -R	AGTTTCTACGGCTTACTCATCAC	
For qPCR: <i>NIITIH4</i> -qF	AAGAAAAGGAAGAAGCAAAAGC	191 bp
<i>NIITIH4</i> -qR	ATGAGTGTAATGACCGAGGGA	
<i>NI18S</i> -qF	GTAACCCGCTGAACCTCC	170 bp
<i>NI18S</i> -qR	GTCCGAAGACCTCACTAAATCA	
<i>Vg</i> -qF	TTCCGTTTGCAGCCACCTATG	154 bp
<i>Vg</i> -qR	CTGCTGCTGCTGCTTCTGTCA	
<i>VgR</i> -qF	AGGCAGCCACACAGATAACCGC	136 bp
<i>VgR</i> -qR	AGCCGCTCGCTCCAGAACATT	
<i>Met</i> -qF	GGTGGTAAACGGATTGGAAA	100 bp
<i>Met</i> -qR	CATCGTCAGCCAACTCGATA	
For dsRNA synthesis: <i>NIITIH4</i> -dsF	GGATCCTAATACGACTCACTATAGGACATCAGTGGTTCCATGT	488 bp
<i>NIITIH4</i> -dsR	GGATCCTAATACGACTCACTATAGGGATCTGTCAAGTTCGACA	
<i>GFP</i> -dsF	GGATCCTAATACGACTCACTATAGGGATACTGTCAGGAGAGGAC	350 bp
<i>GFP</i> -dsR	GGATCCTAATACGACTCACTATAGGGCAGATTGTGTGGACAGG	

2.3. Sequence Comparison and Bioinformatic Analysis

The protein sequence was translated with Protean, and the tertiary structure was predicted by SWISS-MODEL (<https://swissmodel.expasy.org/>) (accessed on 30 September 2019). Transmembrane regions, signal peptides, and isoelectric point were predicted by SignalP 4.1 Server (<http://www.cbs.dtu.dk/services/SignalP/>) (accessed on 30 September 2019). The conserved domain and compound helices were analyzed by SMART (<http://smart.embl-heidelberg.de/>) (accessed on 30 September 2019). The *NIITIH4* protein sequence was compared with other *ITIH4* sequences with NCBI BLAST (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) (accessed on 30 September 2019), and similar sequences were aligned with Lasergene MegAlin ClustalW. An evolutionary tree was constructed with the neighbor-joining method (bootstrap = 1000) using MEGA 10.0 software package [29].

2.4. Double-Strand RNA Synthesis and Injection

Double-strand RNA (dsRNA) was synthesized in vitro by using T7 RNA polymerase and synthetic cDNA templates. Specific primers containing six protective nucleotide bases and the T7 promoter sequence were designed by Primer Premier 5.0 (Table 1). The dsRNA of *NIITIH4* (ds*NIITIH4*) was synthesized in vitro with the template of *NIITIH4* and the primers *NIITIH4*-dsF and *NIITIH4*-dsR (Table 1). The dsRNA of *GFP* (ds*GFP*) was used for the negative control experiment. The *GFP* gene sequence was synthesized in vitro based on the sequence of the binary vector pCAMBIA-1302 (GenBank: AF234298.1) and was cloned into the pMD19-T vector (Takara, Dalian, China). The ds*GFP* was synthesized

in vitro with the template of *GFP* and primers *GFP*-dsF and *GFP*-dsR (Table 1). Then, ds*NITIH4* and ds*GFP* were synthesized according to the instructions of the MEGAscript™ T7 Transcription Kit (Ambion, Austin, TX, USA). A dsRNA synthesis reaction contained 2 µL ATP solution, 2 µL GTP solution, 2 µL CTP solution, 2 µL UTP solution, 1 µg template DNA, 2 µL Enzyme Mix, and 2 µL 10× Reaction Buffer as well as nuclease-free H₂O up to 20 µL. The reaction was incubated at 37 °C for 16 h, then 1 µL TURBO DNase was added, followed by incubation at 37 °C for 15 min. The quality and quantity of the RNA were analyzed as mentioned above.

Newly emerged virgin macropterous female adults were briefly placed on ice for anaesthetization. Approximately 0.05 µL 4000 ng/µL dsRNA (approximately 200 ng) was injected into the mesothorax using a manual microinjector. After injection, female adults were mated with male adults at a ratio of 1:2.

2.5. Real-Time Quantitative PCR Analysis

The expression of target genes in female *N. lugens* samples was analyzed using real-time quantitative PCR (qPCR), and the experiment was repeated three times. To obtain samples from different developmental stages, five adults (one- to five-days old) and multiple nymphs (1st to 5th instar) that were of similar weights (from 0.011 to 0.013 g) were pooled separately for extraction of total RNA. To obtain samples from different tissues, the ovaries, guts, and fat bodies from 30 female adults were dissected and pooled. To obtain samples from dsRNA-treated insects, the entire bodies of five macropterous female adults at various numbers of days post injection of dsRNA (d.p.i.) were pooled.

RNA extraction and cDNA synthesis of these samples were performed as described above. Before carrying out qPCR analysis, the synthesized cDNA solution was diluted 10-fold. The qPCR reagent was SYBR® Premix ExTaq™ II (Tli RNaseH Plus) (Takara, Dalian, China). The specific primers for qPCR were designed, and *N. lugens* 18S rRNA (*Nl18S*) was used as the internal reference (Table 1). A reaction system in the amount of 20 µL was used for qPCR with a StepOnePlus™ Real-Time PCR System (ABI, USA). The 20 µL qPCR reaction volume contained 10 µL 2× SYBR Premix Ex Taq Premix Ex Taq II, 0.4 µL 50× ROX Reference Dye, 2 µL cDNA template, 0.8 µL forward and reverse primers, and 6 µL sterilized ddH₂O, and the reaction program was as follows: 94 °C for 30 s, followed by 40 cycles of 94 °C for 5 s and 60 °C for 30 s. The specificity of primers was detected by melting curve analysis and sequencing, and the relative transcript levels of target genes in different samples were evaluated by the $2^{-\Delta\Delta C_t}$ method [30].

2.6. Survival Rate Statistic, Dissection Observation and Fertility Analysis

Thirty female adults in each treatment group were used to assess effects on survival rates. The experiment was repeated three times.

For tissue observations, 10 female adults at different d.p.i. were used for dissection. The females were dissected in phosphate buffer solution under a Nikon SMZ1500 stereozoom microscope (Nikon, Tokyo, Japan) and photographed with the NIS Elements software (Nikon, Tokyo, Japan). The number of ovarioles at different vitellogenic stages was counted.

For fertility analysis, each treated female adult was placed with two untreated males in a 50 mL centrifuge tube containing fresh rice seedlings that were changed every two days within the 10 d.p.i., and the replaced rice seedlings were maintained independently in new 50 mL tubes. The number of nymphs newly hatched on the seedlings was counted every day until no nymphs hatched, and finally, the seedlings were dissected under the Nikon SMZ1500 stereozoom microscope to observe and count the unhatched eggs. Fifteen female adults were assessed from the two dsRNA-treated groups, and three repetitions were performed.

2.7. Data Analysis

All data were analyzed by one-way analysis of variance (ANOVA), followed by Tukey's test, using the statistical software package SPSS 22 (IBM, Armonk, NY, USA).

Significant differences were considered at $p < 0.01$ or $p < 0.05$, and values are displayed as mean \pm SE.

3. Results

3.1. Identification and Bioinformatic Analysis of *NIITIH4*

NIITIH4 cDNA was found to contain an ORF encoding a protein of 907 amino acids, and the sequence was uploaded to NCBI GenBank (GenBank: MH069652). The protein *NIITIH4* was predicted to have a molecular weight of approximately 100.10 kDa and an isoelectric point (pI) of 6.17. As expected, *NIITIH4* contains a signal peptide and two conserved structural domains: a vault protein inter-alpha-trypsin domain (VIT, 64 aa–175 aa) and a von Willebrand factor type A domain (vWFA, 304 aa–517 aa) (Figure 1). *ITIH4* widely exists in insects, and a sequence comparison showed that *NIITIH4* had highest similarity (48.56%) to *ITIH4* of *Homalodisca vitripennis*, which also belongs to the order Hemiptera with *N. lugens*. A phylogenetic analysis showed that *ITIH4* is conserved in Hemiptera insects (Figure 2). The widespread conservation of *ITIH4* suggests that it has some basic functions in insects.

3.2. Developmental and Tissue-Specific Expression of *NIITIH4*

A qPCR assay was used to detect the developmental and tissue-specific expression of *NIITIH4*, and our results revealed that *NIITIH4* was expressed in different developmental stages and tissues of the female *N. lugens*. In nymphs, the expression level of *NIITIH4* was highest in the second instar nymphs. In female adults, the expression level of *NIITIH4* increased sharply and reached a peak at 2 days after eclosion, then gradually decreased. Moreover, the level of expression of *NIITIH4* was higher in macropterous than in the brachypterous insects (Figure 3A). The expression of *NIITIH4* in the gut, ovary, and fat body of females was also detected, and the results showed that *NIITIH4* in the fat body had the highest transcript level, followed by the ovary (Figure 3B).

3.3. RNAi Effect of *dsNIITIH4* Injection

The results of qPCR analyses showed that the expression of *NIITIH4* in adult female insects treated with *dsNIITIH4* was inhibited by 94.31%, 97.99%, 99.68%, 99.90% and 99.16% at 1 d.p.i., 2 d.p.i., 3 d.p.i., 4 d.p.i. and 5 d.p.i., respectively (Figure 4A), indicating that the *dsNIITIH4* RNAi was effective. In addition, the survival of *N. lugens* was markedly affected by the *dsNIITIH4* injection. The *dsNIITIH4*-treated group had a lower survival rate than did the *dsGFP*-treated group (Figure 4B). At 1 d.p.i., the survival rates of the *dsNIITIH4*-treated group and the *dsGFP*-treated group were 21.36% and 92.40%, respectively. At 4 d.p.i., the survival rates of the *dsNIITIH4*-treated group and the *dsGFP*-treated group were 12.69% and 67.50%, respectively.

The rate of egg production and the hatching rate of eggs were also reduced by the *dsNIITIH4* injection. We counted the number of eggs at 10 d.p.i. to determine the egg-hatching rate. After *dsNIITIH4* treatment, 30 eggs on average were laid by each female, and these eggs had a hatching rate of 63.5%. In this group, the largest number of eggs laid by an individual was 42, and these eggs produced 25 hatched nymphs. After *dsGFP* treatment, each female laid 90 eggs on average with a hatching rate of 87.7%, and the largest number of eggs laid was 180 with 162 hatched nymphs (Figure 4C).

We furthermore dissected the dsRNA-treated female adults to observe their ovaries, and we found that the vitellogenesis of ovarioles was delayed by the *dsNIITIH4* injection. At 2 d.p.i., approximately 90% of ovarioles in *dsGFP*-treated female adults progressed to late or terminal vitellogenesis, but less than 70% of ovarioles in *dsNIITIH4*-treated did so (Figure 4D). The ovarian development of female *N. lugens* was also suppressed by the *dsNIITIH4* injection (Figure 5). At 2 d.p.i., most ovaries had no visible differences between *dsNIITIH4* and *dsGFP* injection, but a morphological difference was observable from 3 d.p.i. At 3 d.p.i., in the *dsGFP*-treated group, the ovaries were normal with many banana-shaped mature eggs, but in the *dsNIITIH4*-treated group, the ovarian development was obviously

delayed, as more incompletely developed eggs were present than in the *dsGFP* group (Figure 5).

```

1  ATG CGG CAC TGC AAT AGT TTA TTG AAC CTT TTT GTC GTT ATT TTG TCG GTG GTC GGT GTT
1  M R H C N S L L N L F V V I L S V V G V
61  GTT GTG GGA CAA CAA CCG GAC ACA ACA ACT TTG GTT GTT ACA ACC GTA AAA GAT GTT GTA
21  V V G Q Q P D T T T L V V T T V K D V V
121 AGT GAT GTG TTT GCA ACA ACA ACT CAA CAA CCC GAG AGC CCT TCA CCA GTC CCG AAG CCA
41  S D V F A T T T Q Q P E S P S P V P K P
181 AAG GTG AGC TCC CTG CAC TAT GAC ACC TCC ATT CAG CAC CGC TAC GCT CGC ACT CAC GTC
61  K V S S L H Y D T S I Q H R Y A R T H V
241 ACC AGC AAG ATC AGC AAC CCG GCT GAG GTG GGC CAA GAG GTG CAC TTC CAG GTC ACT CTG
81  T S K I S N P A E V G Q E V H F Q V T L
301 CCC GAG AAC GCC TTC ATC TCA AAA TTC GTC ATG ACA ATC AAA GAT GTT GGA TAT GAA GCA
101 P E N A F I S K F V M T I K D V G Y E A
361 TAT GTG AAA GAA AAG GAA GAA GCA AAA GCT GAA TAC GAC GCT GCT GTA CAA TCA GGA TTT
121 Y V K E K E E A K A E Y D A A V Q S G F
421 TCA GCA GCT CAC ATT TCA CTC ATA GAT CGT GAT TCG AAT AAA TTT GGC GTA TCT GTG AAC
141 S A A H I S L I D R D S N K F G V S V N
481 GTG GAG GCT GCT GGC AAG GTT CTC TTC AAC TTA ACT TAC GAG GAA TTA CTA ACA AGG TCC
161 V E A A G K V L F N L T Y E E L L T R S
541 CTC GGT CAT TAC ACT CAT ATC ATC AAT GTT AAT CCA GGT CAA ATT GTT AAA GAT TTA GCA
181 L G H Y T H I I N V N P G Q I V K D L A
601 GTC AAA GTA AAA ATT CAA GAA ACA TCA GAT ATC ACA ACG TTG AAA GTA CCT TCA TTC AAA
201 V K V K I Q E T S D I T T L K V P S F K
661 TCA TCA AAT GAT GTG CCT GGA GCA GAA GAA GAA AAC AGA TTG GCG AAA ATC ACC CGC AAC
221 S S N D V P G A E E E N R L A K I T R N
721 CCG AAC AAT GCC AAA GAA GCT GAG ATC AGC TGG TCG CCC GAC TAT GAA CAA CAG AAA GAG
241 P N N A K E A E I S W S P D Y E Q Q K E
781 ATC TCC AAG GAT GGA TTG AAG GGA CGT CTC ATA ATC GAG TAC GAT GTC GAT AGA AAG AAA
261 I S K D G L K G R L I I E Y D V D R K K
841 CAT CCG TCT CAG ATC TTG ATA GAA GGC GGC CAT TTC GTC CAT TTC TTT GCG CCA GCC GAG
281 H P S Q I L I E G G H F V H F F A P A E
901 CTT CCT CCT CTG CGA AAA CAG GTG GTG TTT GTA CTG GAC ATC AGT GGT TCC ATG TTC GGA
301 L P P L R K Q V V F V L D I S G S M F G
961 GAG AAA ATC AAG CAG CTG AAG GAT GCC ATG CTC AAG ATT CTG TCC GAT CTC AAC CCG CAG
321 E K I K Q L K D A M L K I L S D L N P Q
1021 GAT CAC TTC AGT ATT GTA CTT TTC TCT GAT AAT GCC TAT GTG TGG TCC AAA GCT AAG ACT
341 D H F S I V L F S D N A Y V W S K A K T
1081 GCA GTA ATG AAA AAG ATT CTA GAC GAA GGC TTC TAC AAT CTT GAC AAC GAA ACT CTA GCC
361 A V M K K I L D E G F Y N L D N E T L A
1141 ATC TTG GAT GAC CAC AGA AAC GAA ATT CTC CAG GCC ACT CCT GAT AAC GTC AAA ACT GCA
381 I L D D H R N E I L Q A T P D N V K T A
1201 AAG GAG TTC GTC GAA TTG ATT AAG CCA ACT ACA TCA ACC AAC ATA ATT GAT GGC CTG AGA
401 K E F V E L I K P T T S T N I I D G L R
1261 AAG GGA TTA AAG CTG GTG AAA GAA GGA AAG GAA ACA CTG GAT ACC ACC AAA GAG CCA TCC
421 K G L K L V K E G K E T L D T T K E P S
1321 CAG CCT ATC ATG TTC TTC TTG ACT GAT GGA GAA CCC AAT GTC GAC TTG ACA GAT CCC GTG
441 Q P I M F F L T D G E P N V D L T D P V
1381 GAG ATT GTC AAT GAA ACC AGC TCA CTC AAT GAA CAA CTC AAG ACA CCA ATC TAC TCT TTG
461 E I V N E T S S L N E Q L K T P I Y S L
1441 GCA TTT GGT CAG GGG GCT GAC ATA ACT TTC CTG AAG AAA TTG TCA AAG GCT AAC CAC GGA
481 A F G Q G A D I T F L K K L S K A N H G
1501 TTC GCA AGG AAT ATC TAC GAG GGG TCA GAT GCA ACT CTA CAG CTC AAC AAT TTT TAC AAA
501 F A R N I Y E G G S D A T L Q L N N F Y K
1561 GAA ATC TCC TCT CCT CTT CTG GCC AAC GTC ACA TTC ATC TAT CCT CCT GGT GAA GTG GAC
521 E I S S P L L A N V T F I Y P P G E V D

```

Figure 1. Cont.

```

1621 AAC TCA AGC ATA ACA GAT CGC GCG TTC CCG ATC TAC TTC GAG GGC GGC GAA CTG ATT GTG
541 N S S I T D R A F P I Y F E G G E L I V
1681 GTG GGC AAG TTG CGG CGT CAT AAT GCA GCA TCA CGT CCG GCA CTT GAC GCA TCA TTC AAC
561 V G K A L R R H N A A S R P A L D A S F N
1741 ATC GAA ACA AAA CCC GGG CAC ATC GAC CTC AAG AAG CTG GCC GAC ATT GAG TAC CGC TAC
581 I E T K P G H I D L K K L A D I E Y R Y
1801 AGT GAC ATG TGT GGA TCC CCT CCC CTG CTT CCT CGC CCC CAC CCC CAC CCA ATG CCA CCT
601 S D M C G S P P L L P R P H P H P M P P
1861 CTC ATC GCT CCA AAG CCT GAG TAC CAT GGA AAC CTA GAG AAG ATG TGG GCC TAT CTG ACA
621 L I A P K P E Y H G N L E K M W A Y L T
1921 ATC AAA CAG CTT CTG GAG AAA GAC TTG CTA AAC TCT CAA TCC GAC AAC AAC TCA ACC GAG
641 I K Q L L E K D L L N S Q S D N N S T E
1981 AAG CAG AAG GCT CTT CAA TTA GCT CTC CAG TAC AAA TTT GTG ACA CCT CTG ACA TCT CTA
661 K Q K A L Q L A L Q Y K F V T P L T S L
2041 GTG GTG GTG AAA CCG AAC GAA ACG GCC CAG GCG GTG CAA CCA GAG AAA TCG GAC ACC AAA
681 V V V K P N E T A Q A V Q P E K S D T K
2101 CAT GGA TTC CCT GGT GTG GGA TAT GGC GCC CCA GCT GCT GCT GCA TAC CCT GGC ATG TCA
701 H G F P G V G Y G A P A A A A Y P G M S
2161 TTC GGC GCT CCT GCT CCA TCA TAT GGC GCT GCC GGT GGC GGT GGC TTT GCA GCA TAT GGA
721 F G A P A P S Y G A A G G G G F A A Y G
2221 GGA TCT TTC CAT AAT CAC TTC ATG AAT AAA CCA GGA ATG GTG AAT CTC CCT TCA CCT CCG
741 G S F H N H F M N K P G M V N L P S P P
2281 CCT TCA ACA CCT TTC ATT GTT GGA GGA GAT CAA GCT CAA GTT ACC CCT GAT AGA GTC CCT
761 P S T P F I V G G D Q A Q V T P D R V P
2341 GAA ATG AAA GTA ATT CCA TTA AAT CAG CTG AAA TGG CTG AAT ATC ACT GAG AAC CAC CCT
781 E M K V I P L N Q L K W L N I T E N H P
2401 CCA GCT GAG GAG CCA ATC ATT GAA TTT TTG ATC GGT GAA CCA CCC CAA TTC CAG AAC TTC
801 P A E E P I I E F L I G E P P Q F Q N F
2461 ACT GTC GGA ATC AAT AAG ACA AGC AGC TAC TTC GAC CAA TGC ATT TCC CCG GAA GGC GAA
821 T V G I N K T S S Y F D Q C I S P E G E
2521 GGC TTC TGC AAA CAT CTT GAA CAT TGT GCG CTG ACC ACA TTT GAA CTC TAC CCG CAC CAA
841 G F C K H L E H C A L T T F E L Y P H Q
2581 TAC AAA CCA TTC CTC TGT CAG ATC ACA GGT CAA GGC AGC AGT CCA TCG CAA ATC TAC GCT
861 Y K P F L C Q I T G Q G S S P S Q I Y A
2641 GGA GTC TGC TGT CCA ACT AGA TTT GTT TTC CAA CCA CCT CCT CCT CCT CCA CCT CCA TCT
881 G V C C P T R F V F Q P P P P P P P P S
2701 TCT CCA GTG ATG AGT AAG CCG TAG
901 S P V M S K P -
    
```

Figure 1. Nucleotide and encoded amino acid sequences of *NIITI4* ORF. The signal peptide is indicated by a box. The vault protein inter-alpha-trypsin domain is underlined with a dotted line, and the von Willebrand factor type A domain is underlined with a solid line.




Figure 2. A phylogenetic analysis of ITIH4 based on amino acid sequence. Sequences were retrieved

from the NCBI protein database. These sequences included the mammal ITIH4s from *Homo sapiens* (NP_001159921.1), *Sus scrofa* (XP_020924178.1), *Bos taurus* (XP_024838404.1), *Mus pahari* (XP_029397816.1), and all available insect ITIH4s from *Aricia agestis* (XP_041974567.1), *Bombyx mandarina* (XP_028042060.1), *Manduca sexta* (XP_030027688.2), *B. mori* (XP_021202615.2), *Sitophilus oryzae* (XP_030759847.1), *Asbolus verrucosus* (RZB41582.1), *Tribolium madens* (XP_044254677.1), *Lepidoptarsa decemlineata* (XP_023015426.1), *Photinus pyralis* (XP_031349540.1), *Homalodisca vitripennis* (XP_046679415.1), *Rhopalosiphum maidis* (XP_026822307.1), *Aphis craccivora* (KAF0720343.1), *Melanaphis sacchari* (XP_025205475.1), *Myzus persicae* (XP_022172078.1), *Nilaparvata lugens* (QCI55997.1), *Cryptotermes secundus* (XP_023714342.1), *Zootermopsis nevadensis* (XP_021930042.1), *Blattella germanica* (PSN48673.1), and *Thrips palmi* (XP_034239235.1). The phylogenetic tree was constructed with the neighbor-joining method (bootstrap = 1000) using MEGA 10.0.




Figure 3. Expression patterns of *NIITI4* in different developmental stages and tissues. **(A)** Expression of *NIITI4* in different developmental stages, including 1st to 5th instar nymphs, one- to five-days old brachypterous adult females (B1D to B5D) and macropterous adult females (M1D to M5D). **(B)** Expression of *NIITI4* in ovary, gut, and fat body of female adults. Data are expressed as mean \pm SE. Significant differences: * $p < 0.05$, ** $p < 0.01$. Different lower-case letters above the bars indicate significant differences for which $p < 0.05$.

3.4. Effect of RNAi on the Expression of *Vg*, *VgR* and *MeT*

As described above, RNAi exerted by ds*NIITI4* caused adverse effects on the ovarian development of *N. lugens*. In the ovarian development in *N. lugens*, the yolk protein accumulates upon the elevated expression of the gene encoding vitellogenin (*Vg*) after eclosion. We therefore further analyzed the expression of *Vg* and the gene encoding the vitellogenin receptor (*VgR*) [31]. We found that the expression of *Vg* was significantly downregulated after the ds*NIITI4* injection as compared with the expression in control insects treated with ds*GFP* (Figure 6A), indicating that the arrested ovarian development of *N. lugens* upon knockdown of *NIITI4* expression may be due to decreased *Vg* expression. Similarly, the expression of *VgR* was also considerably reduced after the ds*NIITI4* injection as compared with the control (Figure 6B). These results indicate that *NIITI4* may affect the ovarian development of *N. lugens* by regulating the expression of *Vg* and *VgR*. We also examined the relative expression of the gene encoding methoprene-tolerant (*MeT*) from 1 to 4 d.p.i. Over this time, the expression of *MeT* was lowest in both groups at 3 d.p.i. It was upregulated by ds*NIITI4* at 2 and 4 d.p.i. but downregulated at 3 d.p.i. (Figure 6C).




Figure 4. Effects of dsNITIH4 injection on the growth and reproduction of *N. lugens*: (A) the efficiency of RNAi by dsNITIH4 injection at 1 to 5 days post injection of dsRNA (d.p.i.); (B) effect of dsNITIH4 injection on the survival of *N. lugens* at 1 to 4 d.p.i.; (C) effect of dsNITIH4 injection on the number and hatching rate of eggs; and (D) effect of dsNITIH4 injection on the vitellogenesis of ovarioles. EV (early vitellogenesis prophase), MV (middle vitellogenesis), LV (late vitellogenesis), and TV (terminal vitellogenesis) at 1 to 4 d.p.i. Data are expressed as mean ± SE. Significant differences: * $p < 0.05$, ** $p < 0.01$.




Figure 5. Effects of dsRNA injection on ovarian development at 1 to 5 days post injection of dsRNA (d.p.i.). At 1 to 2 d.p.i., there was no visible difference between the ovaries from dsNITIH4-treated and dsGFP-treated groups, but notable differences are present at 3 to 5 d.p.i. Scale bar: 400 μm.




Figure 6. Effects of RNAi on the transcription levels of *Vg* (A), *VgR* (B), *MeT* (C) at 1 to 4 days post injection of dsRNA (d.p.i.). Data are expressed as mean \pm SE. Significant difference: different lower-case letters above the bars indicate significant differences for which $p < 0.05$.

4. Discussion

In the present study, *NIITIH4* was found to be expressed in all developmental stages, and in the fat bodies, ovaries and guts of *N. lugens*, and a ds*NIITIH4* injection notably inhibited the expression of *NIITIH4* in the whole body. This inhibition lowered the survival rate of *N. lugens*. These results indicate that *NIITIH4* is important to the growth and development of *N. lugens*. This importance might be due to the following reasons. Firstly, the silencing of *NIITIH4* may have led to the vWFA domain undergoing destruction, or the binding of key molecules that interact with *NIITIH4*, such as the ITIH4-HA complex, to be affected. This may have induced a decrease in the stability of the extracellular matrix (ECM) and a loss in function of the key molecules, which in turn would cause systemic function damage. *NIITIH4* in this study was found to be carrying a vWFA domain that has multiple interaction surfaces that can bind to various molecules and that are involved in regulating protein–protein interactions of ECM components [32]. ITIH is also involved in maintaining the stability of ECM by binding to HA [19]. In addition, after *NIITIH4* expression was inhibited, the immune system of *N. lugens* may have been altered, because as an acute phase protein (APP), *NIITIH4* may play a role in tissue injury, the response to stressors acting on the body, and non-specific immunity [21,33].

The effect of ds*NIITIH4* RNAi on the ovarian development and reproduction of *N. lugens* was also significant. After RNAi, the ovarian development was delayed, and the production and hatching rate of eggs were reduced. The possible reasons for these results may be explained as follows.

First, after *NIITIH4* was silenced, yolk protein synthesis was blocked and vitellogenesis was delayed, leading to aberrant ovarian development. This alteration, in turn, would be expected to influence egg-laying capacity and egg-hatching. Vitellogenin and its receptor *VgR* play an important role in the synthesis of yolk protein and vitellogenesis [31,34]. Lu et al. [31] showed, for instance, that vitellogenin and the *VgR* were crucial for oocyte maturation and the reproduction of *N. lugens*, and ds*NIVg* RNAi caused oviposition failure. In the present study, the expression of *Vg* and *VgR* was considerably reduced by ds*NIITIH4* RNAi. This mechanism then explains, to some extent, why *N. lugens* reproduction was affected by ds*NIITIH4* RNAi.

In addition, *NIVg*, the precursor of yolk protein, is synthesized primarily in the fat body, then is transported through the hemolymph of the circulatory system and absorbed into the ovary by *NIVgR*-regulated endocytosis. It is ultimately deposited in the ovary, and then the yolk protein is formed [35–37]. Here, we found that *NIITIH4* was most highly expressed in the fat body and ovary. This indicates that there may be some connection or interaction between *NIITIH4* and *NIVg* and *NIVgR*. The silencing of *VgR* could disrupt the uptake of *Vg* into the developing oocyte, and it may result in the accumulation of *Vg* in hemolymph; however, ds*NIVg* RNAi had no effect on *NIVgR* [31]. Since ds*NIITIH4* RNAi

decreased the expression of *NIVgR*, *NIVg* content would be decreased in the ovary and accumulated in the hemolymph.

The Knirps-related nuclear receptor (KNRL) controls vitellin (Vn) breakdown in embryos via the transcriptional inhibition of hydrolases in *N. lugens* [38]. In previous work, the expression levels of five selected trypsin genes and the enzymatic activities of trypsin in embryos were found to be significantly increased after KNRL knockdown, and trypsin injection prolonged egg duration, delayed embryonic development, accelerated Vn breakdown, and severely reduced egg hatchability, a pattern similar to that observed in KNRL-silenced insects [38]. Thus it is also possible that silencing of *NIITIH4* may increasingly affect *Vg* expression through an impact on trypsin activity.

The Juvenile hormone (JH) can stimulate vitellogenesis by activating the synthesis and uptake of *Vg* in *N. lugens*; this may serve as the regulatory basis for oocyte maturation [31,39]. Methoprene-tolerant (MeT) is the receptor for JH and is required for the ovarian development of *N. lugens* [40,41]. In the present study, we detected the expression of *N. lugens MeT* (*NIMet*) after ds*NIITIH4* RNAi. However, the pattern of expression of *NIMet* was not like that of *NIVg* or *NIVgR*. The expression of *NIMet* was downregulated by the ds*NIITIH4* injection only at 3 d.p.i., whereas it was upregulated at 2 and 4 d.p.i.. Similar to the results reported in a study by Lin et al. [41], the expression of *NIMet* decreases when the ovaries of *N. lugens* become mature. The reason why the pattern of expression of *NIMet* was not consistent with that of *Vg* may be due to some feedback regulations in the JH signaling pathway that needs further investigation.

Notably, if ds*NIITIH4* RNAi destroyed the interaction between *NIITIH4* and HA (ITIH4-HA), then the stability of the HA matrix would decrease, and follicular cells or oocyte complex ECM expansion would be blocked. These factors would be expected to impede the maturation of oocytes, fertilization or ovulation, and thus cause the reduction of egg production and hatching rate of *N. lugens* that was observed. Cumulus cells and oocyte complexes and their expansion play an important role in oocyte fertilization, maturation, and ovulation in mammals [42–46]. The formation of the ITIH-HA complex is critical to the construction of the cumulus ECM, and it acts on cumulus oocyte complex expansion, oocyte maturation, fertilization, and ovulation [6,17–19]. A study by Fülöp et al. [47] also showed that the impairment of ITI synthesis or HA binding activity could produce unstable HA and hinder oocyte complex expansion and ovulation. Obayashi et al. [48] showed that the inhibition of ITI-HA binding led to ovulation disorder and loss of the fertilization capacity of oocytes. These results suggest that the *NIITIH4*-HA complex is likely to be destroyed after ds*NIITIH4* RNAi, and it would ultimately affect the ovarian development and egg production of *N. lugens*. In the future, the effects of the ITIH4 and HA binding mechanisms on ovarian development, and the function of *NIITIH4* for reproduction of male *N. lugens*, will be further explored.

The assembly of ovarian muscle ECM may also be affected, and this would cause the decline of ovarian muscle contractility that externally generates a mechanical force to promote ovulation, resulting in difficult ovulation [40]. Apart from these potential factors, the hydrolysis activities of some proteases, the inflammatory reactions, and immunity related to follicle rupture may also be affected by RNAi. As an APP protein, the disruption of *NIITIH4* and the protease inhibitor activity of *NIITI* after ds*NIITIH4* injection would result in the failure of follicle rupture, which in turn would cause a block to ovulation.

Author Contributions: Conceptualization, J.-L.J., S.-J.H. and Y.-P.X.; data curation, S.-J.H. and J.-L.J.; investigation, S.-J.H., J.-L.J., R.-J.Z., J.-B.Y. and Y.-B.L.; supervision, Y.-P.X., G.-F.L. and X.-P.Y.; validation, J.-L.J., S.-J.H. and R.-J.Z.; writing—original draft, J.-L.J.; writing—review and editing, G.-F.L. and Y.-P.X. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by grants from the National Natural Science Foundation of China (31871961, U21A20223 and 31501632), Zhejiang Provincial Key R & D Project (2019C02015, 2022C02047), Natural Science Foundation of Zhejiang Province (LY22C140007), and Fundamental Research Funds for the Provincial Universities of Zhejiang (2020YW14).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Bao, Y.; Zhang, C. Recent advances in molecular biology research of a rice pest, the brown planthopper. *J. Integr. Agric.* **2019**, *18*, 716–728. [[CrossRef](#)]
2. Hu, J.; Xiao, C.; He, Y. Recent progress on the genetics and molecular breeding of brown planthopper resistance in rice. *Rice* **2016**, *9*, 30. [[CrossRef](#)] [[PubMed](#)]
3. Gebhard, W.; Hochstrasser, K.; Fritz, H.; Enghild, J.J.; Pizzo, S.V.; Salvesen, G. Structure of inter-alpha-inhibitor (inter-alpha-trypsin inhibitor) and pre-alpha-inhibitor: Current state and proposition of a new terminology. *Biol. Chem. Hoppe-Seyler* **1990**, *371*, 13–22. [[PubMed](#)]
4. Salier, J.P. Inter-alpha-trypsin inhibitor: Emergence of a family within the Kunitz-type protease inhibitor superfamily. *Trends Biochem. Sci.* **1990**, *15*, 435–439. [[CrossRef](#)]
5. Salier, J.P.; Rouet, P.; Raguenez, G.; Daveau, M. The inter-alpha-inhibitor family: From structure to regulation. *Biochem. J.* **1996**, *315*, 1–9. [[CrossRef](#)]
6. Zhuo, L.; Kimata, K. Structure and function of inter-alpha-trypsin inhibitor heavy chains. *Connect. Tissue Res.* **2008**, *49*, 311–320. [[CrossRef](#)]
7. Enghild, J.J.; Salvesen, G.; Thøgersen, I.B.; Valnickova, Z.; Pizzo, S.V.; Hefta, S.A. Presence of the protein-glycosaminoglycan-protein covalent cross-link in the inter-alpha-inhibitor-related proteinase inhibitor heavy chain 2/bikunin. *J. Biol. Chem.* **1993**, *268*, 8711–8716. [[CrossRef](#)]
8. Zhuo, L.; Hascall, V.C.; Kimata, K. Inter-alpha-trypsin inhibitor, a covalent protein-glycosaminoglycan-protein complex. *J. Biol. Chem.* **2004**, *279*, 38079–38082. [[CrossRef](#)]
9. Fries, E.; Blom, A.M. Bikunin—Not just a plasma proteinase inhibitor. *Int. J. Biochem. Cell Biol.* **2000**, *32*, 125–137. [[CrossRef](#)]
10. Huang, L.; Yoneda, M.; Kimata, K. A serum-derived hyaluronan-associated protein (SHAP) is the heavy chain of the inter alpha-trypsin inhibitor. *J. Biol. Chem.* **1993**, *268*, 26725–26730. [[CrossRef](#)]
11. Yoneda, M.; Suzuki, S.; Kimata, K. Hyaluronic acid associated with the surfaces of cultured fibroblasts is linked to a serum-derived 85-kDa protein. *J. Biol. Chem.* **1990**, *265*, 5247–5257. [[CrossRef](#)]
12. Bost, F.; Diarra-Mehrpour, M.; Martin, J.P. Inter-alpha-trypsin inhibitor proteoglycan family—A group of proteins binding and stabilizing the extracellular matrix. *Eur. J. Biochem.* **1998**, *252*, 339–346. [[CrossRef](#)]
13. Zhao, M.; Yoneda, M.; Ohashi, Y.; Kurono, S.; Iwata, H.; Ohnuki, Y.; Kimata, K. Evidence for the covalent binding of SHAP, heavy chains of inter-alpha-trypsin inhibitor, to hyaluronan. *J. Biol. Chem.* **1995**, *270*, 26657–26663. [[CrossRef](#)]
14. Fraser, J.R.; Laurent, T.C.; Laurent, U.B. Hyaluronan: Its nature, distribution, functions and turnover. *J. Intern. Med.* **1997**, *242*, 27–33. [[CrossRef](#)]
15. Toole, B.P. Hyaluronan: From extracellular glue to pericellular cue. *Nat. Rev. Cancer* **2004**, *4*, 528–539. [[CrossRef](#)]
16. Hutadilok, N.; Ghosh, P.; Brooks, P.M. Binding of haptoglobin, inter-alpha-trypsin inhibitor, and alpha 1 proteinase inhibitor to synovial fluid hyaluronate and the influence of these proteins on its degradation by oxygen derived free radicals. *Ann. Rheum. Dis.* **1988**, *47*, 377–385. [[CrossRef](#)]
17. Geisert, R.D.; Yelich, J.V.; Pratt, T.; Pomp, D. Expression of an inter-alpha-trypsin inhibitor heavy chain-like protein in the pig endometrium during the oestrous cycle and early pregnancy. *J. Reprod. Fertil.* **1998**, *114*, 35–43. [[CrossRef](#)]
18. Zhuo, L.; Yoneda, M.; Zhao, M.; Yingsung, W.; Yoshida, N.; Kitagawa, Y.; Kawamura, K.; Suzuki, T.; Kimata, K. Defect in SHAP-hyaluronan complex causes severe female infertility. A study by inactivation of the bikunin gene in mice. *J. Biol. Chem.* **2001**, *276*, 7693–7696. [[CrossRef](#)]
19. Nagyova, E. The Biological Role of Hyaluronan-Rich Oocyte-Cumulus Extracellular Matrix in Female Reproduction. *Int. J. Mol. Sci.* **2018**, *19*, 283. [[CrossRef](#)]
20. Saguchi, K.; Tobe, T.; Hashimoto, K.; Sano, Y.; Nakano, Y.; Miura, N.H.; Tomita, M. Cloning and characterization of cDNA for inter-alpha-trypsin inhibitor family heavy chain-related protein (IHRP), a novel human plasma glycoprotein. *J. Biochem.* **1995**, *117*, 14–18. [[CrossRef](#)]
21. Choi-Miura, N.H.; Takahashi, K.; Yoda, M.; Saito, K.; Hori, M.; Ozaki, H.; Mazda, T.; Tomita, M. The novel acute phase protein, IHRP, inhibits actin polymerization and phagocytosis of polymorphonuclear cells. *Inflamm. Res.* **2000**, *49*, 305–310. [[CrossRef](#)]
22. Piñeiro, M.; Andrés, M.; Iturralde, M.; Carmona, S.; Hirvonen, J.; Pyörälä, S.; Heegaard, P.M.; Tjørnehøj, K.; Lampreave, F.; Piñeiro, A.; et al. ITIH4 (inter-alpha-trypsin inhibitor heavy chain 4) is a new acute-phase protein isolated from cattle during experimental infection. *Infect. Immun.* **2004**, *72*, 3777–3782. [[CrossRef](#)]
23. Duan, X.; Yarmush, D.; Berthiaume, F.; Jayaraman, A.; Yarmush, M.L. Immunodepletion of albumin for two-dimensional gel detection of new mouse acute-phase protein and other plasma proteins. *Proteomics* **2005**, *5*, 3991–4000. [[CrossRef](#)]
24. Nayak, A.R.; Kashyap, R.S.; Kabra, D.; Purohit, H.J.; Taori, G.M.; Daginawala, H.F. Time course of inflammatory cytokines in acute ischemic stroke patients and their relation to inter-alfa trypsin inhibitor heavy chain 4 and outcome. *Ann. Indian Acad. Neurol.* **2012**, *15*, 181–185. [[CrossRef](#)]

25. Huang, M.; Zhang, W.; Zhao, B.; Li, L. Relationship between inter- α -trypsin inhibitor heavy chain 4 and ovarian cancer. *Chin. J. Cancer Res.* **2019**, *31*, 955–964. [[CrossRef](#)]
26. Fung, E.T.; Yip, T.T.; Lomas, L.; Wang, Z.; Yip, C.; Meng, X.Y.; Lin, S.; Zhang, F.; Zhang, Z.; Chan, D.W.; et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. *Int. J. Cancer* **2005**, *115*, 783–789. [[CrossRef](#)]
27. Esplin, M.S.; Merrell, K.; Goldenberg, R.; Lai, Y.; Iams, J.D.; Mercer, B.; Spong, C.Y.; Miodovnik, M.; Simhan, H.N.; van Dorsten, P.; et al. Proteomic identification of serum peptides predicting subsequent spontaneous preterm birth. *Am. J. Obstet. Gynecol.* **2011**, *204*, 391.e1–391.e8. [[CrossRef](#)]
28. Soler, L.; Dąbrowski, R.; García, N.; Alava, M.A.; Lampreave, F.; Piñeiro, M.; Wawron, W.; Szczubiał, M.; Bochniarz, M. Acute-phase inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) levels in serum and milk of cows with subclinical mastitis caused by *Streptococcus* species and coagulase-negative *Staphylococcus* species. *J. Dairy Sci.* **2019**, *102*, 539–546. [[CrossRef](#)]
29. Kumar, S.; Stecher, G.; Li, M.; Niyaz, C.; Tamura, K. MEGA X: Molecular evolutionary genetics analysis across computing platforms. *Mol. Biol. Evol.* **2018**, *35*, 1547–1549. [[CrossRef](#)]
30. Livak, K.J.; Schmittgen, T.D. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the $2^{-\Delta\Delta CT}$ Method. *Methods* **2001**, *25*, 402–408. [[CrossRef](#)]
31. Lu, K.; Shu, Y.; Zhou, J.; Zhang, X.; Zhang, X.; Chen, M.; Yao, Q.; Zhou, Q.; Zhang, W. Molecular characterization and RNA interference analysis of vitellogenin receptor from *Nilaparvata lugens* (Stål). *J. Insect Physiol.* **2015**, *73*, 20–29. [[CrossRef](#)] [[PubMed](#)]
32. Springer, T.A. Complement and the multifaceted functions of VWA and integrin I domains. *Structure* **2006**, *14*, 1611–1616. [[CrossRef](#)] [[PubMed](#)]
33. Cray, C. Acute phase proteins in animals. *Prog. Mol. Biol. Transl. Sci.* **2012**, *105*, 113–150. [[CrossRef](#)]
34. Tiu, S.H.; Benzie, J.; Chan, S.M. From hepatopancreas to ovary: Molecular characterization of a shrimp vitellogenin receptor involved in the processing of vitellogenin. *Biol. Reprod.* **2008**, *79*, 66–74. [[CrossRef](#)] [[PubMed](#)]
35. Pan, M.L.; Bell, W.J.; Telfer, W.H. Vitellogenic blood protein synthesis by insect fat body. *Science* **1969**, *165*, 393–394. [[CrossRef](#)] [[PubMed](#)]
36. Shen, Y.; Chen, Y.; Lou, Y.; Zhang, C. Vitellogenin and Vitellogenin-Like Genes in the Brown Planthopper. *Front. Physiol.* **2019**, *10*, 1181. [[CrossRef](#)]
37. Yuan, L.J.; Peng, C.; Liu, B.H.; Feng, J.B.; Qiu, G.F. Identification and Characterization of a Luteinizing Hormone Receptor (LHR) Homolog from the Chinese Mitten Crab *Eriocheir sinensis*. *Int. J. Mol. Sci.* **2019**, *20*, 1736. [[CrossRef](#)]
38. Lu, K.; Cheng, Y.; Li, Y.; Li, W.; Song, Y.; Zeng, R.; Sun, Z. The KNRL nuclear receptor controls hydrolase-mediated vitellin breakdown during embryogenesis in the brown planthopper, *Nilaparvata lugens*. *Insect Sci.* **2021**, *28*, 1633–1650. [[CrossRef](#)]
39. Bertuso, A.G.; Morooka, S.; Tojo, S. Sensitive periods for wing development and precocious metamorphosis after precocene treatment of the brown planthopper, *Nilaparvata lugens*. *J. Insect Physiol.* **2002**, *48*, 221–229. [[CrossRef](#)]
40. Luo, W.; Liu, S.; Zhang, W.; Yang, L.; Huang, J.; Zhou, S.; Feng, Q.; Palli, S.R.; Wang, J.; Roth, S.; et al. Juvenile hormone signaling promotes ovulation and maintains egg shape by inducing expression of extracellular matrix genes. *Proc. Natl. Acad. Sci. USA* **2021**, *118*, e2104461118. [[CrossRef](#)]
41. Lin, X.; Yao, Y.; Wang, B. Methoprene-tolerant (Met) and Krüppel-homologue 1 (Kr-h1) are required for ovariole development and egg maturation in the brown plant hopper. *Sci. Rep.* **2015**, *5*, 18064. [[CrossRef](#)]
42. Robker, R.L.; Hennebold, J.D.; Russell, D.L. Coordination of Ovulation and Oocyte Maturation: A Good Egg at the Right Time. *Endocrinology* **2018**, *159*, 3209–3218. [[CrossRef](#)]
43. Vigone, G.; Shuhaibar, L.C.; Egbert, J.R.; Uliasz, T.F.; Movsesian, M.A.; Jaffe, L.A. Multiple cAMP Phosphodiesterases Act Together to Prevent Premature Oocyte Meiosis and Ovulation. *Endocrinology* **2018**, *159*, 2142–2152. [[CrossRef](#)]
44. Gérard, N.; Robin, E. Cellular and molecular mechanisms of the preovulatory follicle differentiation and ovulation: What do we know in the mare relative to other species. *Theriogenology* **2019**, *130*, 163–176. [[CrossRef](#)]
45. Vanderhyden, B.C.; Armstrong, D.T. Role of cumulus cells and serum on the in vitro maturation, fertilization, and subsequent development of rat oocytes. *Biol. Reprod.* **1989**, *40*, 720–728. [[CrossRef](#)]
46. Zhuo, L.; Kimata, K. Cumulus oophorus extracellular matrix: Its construction and regulation. *Cell Struct. Funct.* **2001**, *26*, 189–196. [[CrossRef](#)]
47. Fülöp, C.; Szántó, S.; Mukhopadhyay, D.; Bárdos, T.; Kamath, R.V.; Rugg, M.S.; Day, A.J.; Salustri, A.; Hascall, V.C.; Glant, T.T.; et al. Impaired cumulus mucification and female sterility in tumor necrosis factor-induced protein-6 deficient mice. *Development* **2003**, *130*, 2253–2261. [[CrossRef](#)]
48. Obayashi, Y.; Yabushita, H.; Kanyama, K.; Noguchi, M.; Zhuo, L.; Kimata, K.; Wakatsuki, A. Role of serum-derived hyaluronan-associated protein-hyaluronan complex in ovarian cancer. *Oncol. Rep.* **2008**, *19*, 1245–1251. [[CrossRef](#)]